Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.

MLA

Tang, Yi, and Haiqiang Sang. “Cost‐utility Analysis of Add‐on Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction.” ESC Heart Failure, vol. 10, no. 4, Aug. 2023, pp. 2524–33. EBSCOhost, https://doi.org/10.1002/ehf2.14426.

APA

Tang, Y., & Sang, H. (2023). Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction. ESC Heart Failure, 10(4), 2524–2533. https://doi.org/10.1002/ehf2.14426

Chicago

Tang, Yi, and Haiqiang Sang. 2023. “Cost‐utility Analysis of Add‐on Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction.” ESC Heart Failure 10 (4): 2524–33. doi:10.1002/ehf2.14426.